Dose: 200 to 800 mg
Single Dose: 500 (500)
Frequency: As recommended.
Route: Slow IV
Instructions: Over 2.5-10 Minutes

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

. It is of Semi Synthetic origin and belongs to Carboxylic acid lactone. It belongs to Aldosterone antagonist pharmacological group on the basis of mechanism of action and also classified in Diuretic Potassium Sparing pharmacological group.The Molecular Weight of Potassium Canrenoate is 396.20. Its pKa is 5.2.

Potassium Canrenoate is contraindicated in conditions like Hyperkalaemia,Renal diseases.

The severe or irreversible adverse effects of Potassium Canrenoate, which give rise to further complications include Hoarseness, Deepening of voice, Pitch elevation in men.Potassium Canrenoate produces potentially life-threatening effects which include Hyperkalemia. which are responsible for the discontinuation of Potassium Canrenoate therapy.The signs and symptoms that are produced after the acute overdosage of Potassium Canrenoate include Nausea, Vomiting, Confusion, Hallucinations, Restlessness.The symptomatic adverse reactions produced by Potassium Canrenoate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Gynecomastia, Menstrual irregularity, Pain at injection site.

Potassium Canrenoate is primarily indicated in conditions like Magnesium deficiency, Oedema with secondary aldosteronism, Potassium deficiency, Primary hyperaldosteronism.

No data regarding the interactions of Potassium Canrenoate was found.

Measurement of Serum Digoxin Level by radioimmunoassay Measurement of Corticosteroid, 17-Ketosteroids, 17-OH Corticosteroids & 11-OH Corticosteroids

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Serum electrolytes and blood urea nitrogen should be measured periodically. It should be used carefully in patient who are at increased risk of developing hyperkalemia, such as elderly, those with diabetes mellitus and those with some degree of renal or hepatic impairment and patients likely to develop acidosis.